Instructions for Progynova (Estradiol) 2 mg 21 dragee
English product name
Progynova
Release form
dragee
Description:
dragee 1 person
estradiol valerate 2 mg
Auxiliary substances:
lactose monohydrate - 46.25 mg,
cornstarch - 26.2 mg,
povidon 25000 - 3 mg,
talc - 2.4 mg,
magnesium stearate - 0.15 mg,
sucrose crystalline - 33.54 mg,
povidon 700000 - 0.323 mg,
macrogol 6000 - 3.719 mg,
calcium carbonate precipitated - 14.572 mg,
talc - 7.104 mg,
glycerol 85% - 0.205 mg,
titanium dioxide (E) 171) - 0.411 mg,
indigocarmine (E132) - 0.051 mg,
montanglycolic wax - 0.075 mg.
21 pcs. - blister packs (1) - cardboard packs.
ATC codes
G03CA03 Estradiol
Clinical-pharmacological groups / Group affiliation Progynova
Anti-climacteric estrogen preparation
Active substance
Estradiol valerate
Pharmacotherapy group Progynova
Estrogen
Pharmacological effect Progynova:
Estrogen, a replacement therapy agent. Estradiol valerate has a specific estrogenic effect: it causes endometrial proliferation, stimulates the development of the uterus and secondary female genital signs in the event of their underdevelopment, and mitigates and eliminates general disorders arising in the woman's body on the grounds of insufficient function of the genital glands in the climacteric period or after gynecological operations.
Estradiol valerate maintains the balance between osteoblasts and osteoclasts, reduces bone resorption and promotes its formation.
Testimony Progynova:
- High tides, excessive sweating,
- sleep disorders,
- depression,
- nervousness,
- irritability,
- headaches,
- dizziness in case of menstruation termination during menstruation,
- after rapid removal of ovaries or their irradiation;
- bladder hyperesthesia,
- degenerative skin and mucous membrane changes,
- osteoporosis in the climacteric period.
Method of use, course and dosage:
If ingested, the daily dose is one to two mg. The treatment depends on the indications.
Application for kidney disorders
It is contraindicated in severe kidney dysfunction.
Use in liver disorders Estradiol
It is contraindicated in cases of severe liver dysfunction and liver tumors. The use is also contraindicated if hepatitis, jaundice were observed during the previous pregnancy.
- Nosology Progynova (ICD codes)
- M80.0
- Postmenopausal osteoporosis with pathological fracture
- M80.1
- Osteoporosis with pathological fracture after ovarian removal
- M81.0
- Postmenopausal osteoporosis
- M81.1
- Osteoporosis after ovarian removal
- N33.8
- Bladder lesions for other diseases classified in other rubrics
- N95.1
- Menopause and Menopause in Women
- N95.2
- Postmenopausal atrophic vaginitis
- N95.3
- Conditions associated with artificially induced menopause
